Genprex Inc GNPX

NAS: GNPX | ISIN: US3724461047   14/11/2024
1,640 USD (+2,50%)
(+2,50%)   14/11/2024

9 september 2024 · Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics · Persbericht

4 september 2024 · Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes · Persbericht

3 september 2024 · Genprex to Present and Participate at Upcoming September Investor and Industry Conferences · Persbericht

15 augustus 2024 · Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials · Persbericht

14 augustus 2024 · Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer · Persbericht

13 augustus 2024 · Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers · Persbericht

8 augustus 2024 · Genprex to Present at the August Sidoti Microcap Conference · Persbericht

27 juni 2024 · Genprex Issues Stockholder Letter and Provides 2024 Corporate Update · Persbericht

30 mei 2024 · Genprex to Present at the 2024 BIO International Convention · Persbericht

14 mei 2024 · Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

13 mei 2024 · Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors · Persbericht

9 mei 2024 · Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner · Persbericht

1 mei 2024 · Genprex to Present and Participate at Upcoming May Investor and Industry Conferences · Persbericht

9 april 2024 · Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting · Persbericht

3 april 2024 · Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

2 april 2024 · Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System · Persbericht

22 maart 2024 · Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

12 maart 2024 · Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers · Persbericht

Mijn selecties